{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:28:58Z","timestamp":1786667338704,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Science and Technology Research Project","doi-asserted-by":"crossref","award":["242102311089"],"award-info":[{"award-number":["242102311089"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171983"],"award-info":[{"award-number":["82171983"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-54570-5","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:18:41Z","timestamp":1780539521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MAPK pathway inhibitors enhance radioiodine sensitivity in anaplastic thyroid carcinoma through promoting NIS expression and ARF4-mediated NIS membrane transport"],"prefix":"10.1038","volume":"16","author":[{"given":"Junfang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shasha","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keliu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongguang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingmin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"54570_CR1","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch, Z. W. et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3 (2022).","journal-title":"Endocr. Pathol."},{"key":"54570_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3803\/EnM.2022.1553","volume":"37","author":"CK Jung","year":"2022","unstructured":"Jung, C. K., Bychkov, A. & Kakudo, K. Update from the 2022 World Health Organization classification of thyroid tumors: A standardized diagnostic approach. Endocrinol. Metab. 37, 703\u2013718. https:\/\/doi.org\/10.3803\/EnM.2022.1553 (2022).","journal-title":"Endocrinol. Metab."},{"key":"54570_CR3","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"Maniakas, A. et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncol. 6, 1397. https:\/\/doi.org\/10.1001\/jamaoncol.2020.3362 (2020).","journal-title":"JAMA Oncol."},{"key":"54570_CR4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"Landa, I. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126, 1052\u20131066. https:\/\/doi.org\/10.1172\/JCI85271 (2016).","journal-title":"J. Clin. Invest."},{"key":"54570_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2024.100661","volume":"5","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations. Innovation 5, 100661. https:\/\/doi.org\/10.1016\/j.xinn.2024.100661 (2024).","journal-title":"Innovation"},{"key":"54570_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1530\/ERC-13-0399","volume":"21","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z., Liu, D., Murugan, A. K., Liu, Z. & Xing, M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr. Relat. Cancer 21, 161\u2013173. https:\/\/doi.org\/10.1530\/ERC-13-0399 (2014).","journal-title":"Endocr. Relat. Cancer"},{"key":"54570_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/ajco.13836","volume":"19","author":"Q Yu","year":"2023","unstructured":"Yu, Q. et al. Molecular basis and targeted therapies for radioiodine refractory thyroid cancer. Asia Pac. J. Clin. Oncol. 19, 279\u2013289. https:\/\/doi.org\/10.1111\/ajco.13836 (2023).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"54570_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1089\/thy.2023.0456","volume":"34","author":"D Toro-Tobon","year":"2024","unstructured":"Toro-Tobon, D. et al. Clinical outcomes of radioactive iodine redifferentiation therapy in previously iodine refractory differentiated thyroid cancers. Thyroid 34, 70\u201381. https:\/\/doi.org\/10.1089\/thy.2023.0456 (2024).","journal-title":"Thyroid"},{"key":"54570_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.2967\/jnumed.118.216721","volume":"60","author":"O ElMokh","year":"2019","unstructured":"ElMokh, O. et al. MEK inhibition induces therapeutic iodine uptake in a murine model of anaplastic thyroid cancer. J. Nucl. Med. 60, 917\u2013923. https:\/\/doi.org\/10.2967\/jnumed.118.216721 (2019).","journal-title":"J. Nucl. Med."},{"key":"54570_CR10","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 368, 623\u2013632. https:\/\/doi.org\/10.1056\/NEJMoa1209288 (2013).","journal-title":"N. Engl. J. Med."},{"key":"54570_CR11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1210\/jc.2018-01478","volume":"104","author":"LA Dunn","year":"2019","unstructured":"Dunn, L. A. et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J. Clin. Endocrinol. Metab. 104, 1417\u20131428. https:\/\/doi.org\/10.1210\/jc.2018-01478 (2019).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54570_CR12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1158\/1078-0432.CCR-23-0046","volume":"29","author":"S Leboulleux","year":"2023","unstructured":"Leboulleux, S. et al. A phase II redifferentiation trial with dabrafenib-trametinib and 131I in metastatic radioactive iodine refractory BRAF p.V600E-mutated differentiated thyroid cancer. Clin. Cancer Res. 29, 2401\u20132409. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0046 (2023).","journal-title":"Clin. Cancer Res."},{"key":"54570_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1677\/erc.1.01119","volume":"13","author":"G Riesco-Eizaguirre","year":"2006","unstructured":"Riesco-Eizaguirre, G., Guti\u00e9rrez-Mart\u00ednez, P., Garc\u00eda-Cabezas, M. A., Nistal, M. & Santisteban, P. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+\/I\u2212 targeting to the membrane. Endocr. Relat. Cancer 13, 257\u2013269. https:\/\/doi.org\/10.1677\/erc.1.01119 (2006).","journal-title":"Endocr. Relat. Cancer"},{"key":"54570_CR14","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1210\/jcem.86.6.7746","volume":"86","author":"O Doh\u00e1n","year":"2001","unstructured":"Doh\u00e1n, O., Baloch, Z., B\u00e1nr\u00e9vi, Z., Livolsi, V. & Carrasco, N. RAPID COMMUNICATION: Predominant intracellular overexpression of the Na+\/I\u2212 symporter (NIS) in a large sampling of thyroid cancer cases. J. Clin. Endocrinol. Metab. 86, 2697\u20132700. https:\/\/doi.org\/10.1210\/jcem.86.6.7746 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54570_CR15","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1210\/jc.2002-021544","volume":"88","author":"IL Wapnir","year":"2003","unstructured":"Wapnir, I. L. et al. Immunohistochemical profile of the sodium\/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J. Clin. Endocrinol. Metab. 88, 1880\u20131888. https:\/\/doi.org\/10.1210\/jc.2002-021544 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54570_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/0008-5472.CAN-19-1957","volume":"80","author":"A Fletcher","year":"2020","unstructured":"Fletcher, A. et al. Targeting novel sodium iodide symporter interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein enhances radioiodine uptake. Cancer Res. 80, 102\u2013115. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-1957 (2020).","journal-title":"Cancer Res."},{"key":"54570_CR17","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1091\/mbc.e13-04-0197","volume":"24","author":"W Nakai","year":"2013","unstructured":"Nakai, W. et al. ARF1 and ARF4 regulate recycling endosomal morphology and retrograde transport from endosomes to the Golgi apparatus. Mol. Biol. Cell 24, 2570\u20132581. https:\/\/doi.org\/10.1091\/mbc.e13-04-0197 (2013).","journal-title":"Mol. Biol. Cell"},{"key":"54570_CR18","doi-asserted-by":"publisher","first-page":"35634","DOI":"10.1074\/jbc.M111.261800","volume":"286","author":"V Popoff","year":"2011","unstructured":"Popoff, V. et al. Several ADP-ribosylation factor (ARF) isoforms support COPI vesicle formation. J. Biol. Chem. 286, 35634\u201335642. https:\/\/doi.org\/10.1074\/jbc.M111.261800 (2011).","journal-title":"J. Biol. Chem."},{"key":"54570_CR19","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1093\/neuonc\/noae059","volume":"26","author":"S Budhiraja","year":"2024","unstructured":"Budhiraja, S. et al. ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma. Neuro-Oncol. 26, 1421\u20131437. https:\/\/doi.org\/10.1093\/neuonc\/noae059 (2024).","journal-title":"Neuro-Oncol."},{"key":"54570_CR20","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1089\/thy.2022.0504","volume":"33","author":"X Zhao","year":"2023","unstructured":"Zhao, X. et al. Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: A single-center retrospective cohort study. Thyroid 33, 484\u2013491. https:\/\/doi.org\/10.1089\/thy.2022.0504 (2023).","journal-title":"Thyroid"},{"key":"54570_CR21","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1210\/jc.2007-1184","volume":"92","author":"DW Ball","year":"2007","unstructured":"Ball, D. W. et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1\/2 inhibitor AZD6244. J. Clin. Endocrinol. Metab. 92, 4712\u20134718. https:\/\/doi.org\/10.1210\/jc.2007-1184 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"54570_CR22","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jss.2013.03.052","volume":"184","author":"E Kandil","year":"2013","unstructured":"Kandil, E. et al. Synergistic inhibition of thyroid cancer by suppressing MAPK\/PI3K\/AKT pathways. J. Surg. Res. 184, 898\u2013906. https:\/\/doi.org\/10.1016\/j.jss.2013.03.052 (2013).","journal-title":"J. Surg. Res."},{"key":"54570_CR23","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-24-0209","volume":"32","author":"Z Li","year":"2025","unstructured":"Li, Z., Song, L., Yang, Y., Zhao, Y. & Ma, S. Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer. Endocr. Relat. Cancer 32, e240209. https:\/\/doi.org\/10.1530\/ERC-24-0209 (2025).","journal-title":"Endocr. Relat. Cancer"},{"key":"54570_CR24","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2967\/jnumed.122.264913","volume":"64","author":"J Taprogge","year":"2023","unstructured":"Taprogge, J. et al. The role of pretherapy quantitative imaging and dosimetry in radioiodine therapy for advanced thyroid cancer. J. Nucl. Med. 64, 1125\u20131130. https:\/\/doi.org\/10.2967\/jnumed.122.264913 (2023).","journal-title":"J. Nucl. Med."},{"key":"54570_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.yexcr.2015.08.003","volume":"338","author":"C Ingeson-Carlsson","year":"2015","unstructured":"Ingeson-Carlsson, C., Martinez-Monleon, A. & Nilsson, M. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAFV600E mutant thyroid cancer cells in 2D and 3D culture. Exp. Cell Res. 338, 127\u2013135. https:\/\/doi.org\/10.1016\/j.yexcr.2015.08.003 (2015).","journal-title":"Exp. Cell Res."},{"key":"54570_CR26","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.radonc.2015.08.025","volume":"117","author":"AM Baschnagel","year":"2015","unstructured":"Baschnagel, A. M. et al. The association of 18F-FDG PET and glucose metabolism biomarkers GLUT1 and HK2 in p16 positive and negative head and neck squamous cell carcinomas. Radiother. Oncol. 117, 118\u2013124. https:\/\/doi.org\/10.1016\/j.radonc.2015.08.025 (2015).","journal-title":"Radiother. Oncol."},{"key":"54570_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/RLU.0b013e3182393599","volume":"37","author":"F Grabellus","year":"2012","unstructured":"Grabellus, F., Nagarajah, J., Bockisch, A., Schmid, K. W. & Sheu, S.-Y. Glucose transporter 1 expression, tumor proliferation, and iodine\/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin. Nucl. Med. 37, 121\u2013127. https:\/\/doi.org\/10.1097\/RLU.0b013e3182393599 (2012).","journal-title":"Clin. Nucl. Med."},{"key":"54570_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.2967\/jnumed.114.150607","volume":"56","author":"J Nagarajah","year":"2015","unstructured":"Nagarajah, J., Ho, A. L., Tuttle, R. M., Weber, W. A. & Grewal, R. K. Correlation of BRAFV600E mutation and glucose metabolism in thyroid cancer patients: An 18F-FDG PET study. J. Nucl. Med. 56, 662\u2013667. https:\/\/doi.org\/10.2967\/jnumed.114.150607 (2015).","journal-title":"J. Nucl. Med."},{"key":"54570_CR29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.ajpath.2011.11.026","volume":"180","author":"JJ-C Sheu","year":"2012","unstructured":"Sheu, J.J.-C. et al. Mutant BRAF induces DNA strand breaks, activates DNA damage response pathway, and up-regulates glucose transporter-1 in nontransformed epithelial cells. Am. J. Pathol. 180, 1179\u20131188. https:\/\/doi.org\/10.1016\/j.ajpath.2011.11.026 (2012).","journal-title":"Am. J. Pathol."},{"key":"54570_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/ERC-20-0135","volume":"27","author":"M Wagner","year":"2020","unstructured":"Wagner, M. et al. Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer. Endocr. Relat. Cancer 27, 495\u2013507. https:\/\/doi.org\/10.1530\/ERC-20-0135 (2020).","journal-title":"Endocr. Relat. Cancer"},{"key":"54570_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1089\/thy.2010.0008","volume":"20","author":"MS Fenton","year":"2010","unstructured":"Fenton, M. S. et al. Sunitinib inhibits MEK\/ERK and SAPK\/JNK pathways and increases sodium\/iodide symporter expression in papillary thyroid cancer. Thyroid 20, 965\u2013974. https:\/\/doi.org\/10.1089\/thy.2010.0008 (2010).","journal-title":"Thyroid"},{"key":"54570_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02813-6","volume":"22","author":"H Samimi","year":"2022","unstructured":"Samimi, H. et al. BI-847325, a selective dual MEK and aurora kinases inhibitor, reduces aggressive behavior of anaplastic thyroid carcinoma on an in vitro three-dimensional culture. Cancer Cell Int. 22, 388. https:\/\/doi.org\/10.1186\/s12935-022-02813-6 (2022).","journal-title":"Cancer Cell Int."},{"key":"54570_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19072077","volume":"19","author":"S W\u00e4chter","year":"2018","unstructured":"W\u00e4chter, S. et al. Selumetinib activity in thyroid cancer cells: Modulation of Sodium Iodide Symporter and associated miRNAs. Int. J. Mol. Sci. 19, 2077. https:\/\/doi.org\/10.3390\/ijms19072077 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"54570_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031077","volume":"22","author":"YJ Choi","year":"2021","unstructured":"Choi, Y. J. et al. Tunicamycin as a novel redifferentiation agent in radioiodine therapy for anaplastic thyroid cancer. Int. J. Mol. Sci. 22, 1077. https:\/\/doi.org\/10.3390\/ijms22031077 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"54570_CR35","doi-asserted-by":"publisher","first-page":"5069","DOI":"10.1158\/1078-0432.CCR-18-3007","volume":"25","author":"TD Singh","year":"2019","unstructured":"Singh, T. D. et al. A novel orally active inverse agonist of estrogen-related receptor gamma (ERR\u03b3), DN200434, a booster of NIS in anaplastic thyroid cancer. Clin. Cancer Res. 25, 5069\u20135081. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3007 (2019).","journal-title":"Clin. Cancer Res."},{"key":"54570_CR36","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.2021.0191","volume":"32","author":"C Fern\u00e1ndez-M\u00e9ndez","year":"2022","unstructured":"Fern\u00e1ndez-M\u00e9ndez, C. & Santisteban, P. A critical balance between PAX8 and the hippo mediator TAZ determines sodium\/iodide symporter expression and function. Thyroid 32, 315\u2013325. https:\/\/doi.org\/10.1089\/thy.2021.0191 (2022).","journal-title":"Thyroid"},{"key":"54570_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-019-0322-x","volume":"17","author":"N Kaushik","year":"2019","unstructured":"Kaushik, N. et al. Low dose radiation regulates BRAF-induced thyroid cellular dysfunction and transformation. Cell Commun. Signal. 17, 12. https:\/\/doi.org\/10.1186\/s12964-019-0322-x (2019).","journal-title":"Cell Commun. Signal."},{"key":"54570_CR38","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1039\/D1FO01073E","volume":"12","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Curcumin enhances the membrane trafficking of the sodium iodide symporter and augments radioiodine uptake in dedifferentiated thyroid cancer cells via suppression of the PI3K-AKT signaling pathway. Food Funct. 12, 8260\u20138273. https:\/\/doi.org\/10.1039\/D1FO01073E (2021).","journal-title":"Food Funct."},{"key":"54570_CR39","doi-asserted-by":"publisher","first-page":"30907","DOI":"10.18632\/oncotarget.9023","volume":"7","author":"BP Danysh","year":"2016","unstructured":"Danysh, B. P. et al. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model. Oncotarget 7, 30907\u201330923. https:\/\/doi.org\/10.18632\/oncotarget.9023 (2016).","journal-title":"Oncotarget"},{"key":"54570_CR40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1089\/thy.2022.0533","volume":"33","author":"AV Nikitski","year":"2023","unstructured":"Nikitski, A. V., Condello, V., Divakaran, S. S. & Nikiforov, Y. E. Inhibition of ALK-signaling overcomes STRN-ALK-induced downregulation of the sodium iodine symporter and restores radioiodine uptake in thyroid cells. Thyroid 33, 464\u2013473. https:\/\/doi.org\/10.1089\/thy.2022.0533 (2023).","journal-title":"Thyroid"},{"key":"54570_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215460","volume":"13","author":"M Faria","year":"2021","unstructured":"Faria, M., Domingues, R., Bugalho, M. J., Silva, A. L. & Matos, P. Analysis of NIS plasma membrane interactors discloses key regulation by a SRC\/RAC1\/PAK1\/PIP5K\/EZRIN pathway with potential implications for radioiodine re-sensitization therapy in thyroid cancer. Cancers 13, 5460. https:\/\/doi.org\/10.3390\/cancers13215460 (2021).","journal-title":"Cancers"},{"key":"54570_CR42","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.7150\/thno.57689","volume":"11","author":"JM Oh","year":"2021","unstructured":"Oh, J. M. & Ahn, B.-C. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS. Theranostics 11, 6251\u20136277 (2021).","journal-title":"Theranostics"},{"key":"54570_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx092","author":"M Amit","year":"2017","unstructured":"Amit, M. et al. Post-translational regulation of radioactive iodine therapy response in papillary thyroid carcinoma. JNCI J. Natl. Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djx092 (2017).","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"54570_CR44","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3892\/or.2016.5228","volume":"37","author":"L Lan","year":"2017","unstructured":"Lan, L. et al. Inhibiting \u03b2-catenin expression promotes efficiency of radioiodine treatment in aggressive follicular thyroid cancer cells probably through mediating NIS localization. Oncol. Rep. 37, 426\u2013434. https:\/\/doi.org\/10.3892\/or.2016.5228 (2017).","journal-title":"Oncol. Rep."},{"key":"54570_CR45","doi-asserted-by":"publisher","unstructured":"\u201cBRAFV600E restructures cellular lactylation to promote anaplastic thyroid cancer proliferation\u201d 2023. Endocrine-Related Cancer 30. https:\/\/doi.org\/10.1530\/ERC-22-0344","DOI":"10.1530\/ERC-22-0344"},{"key":"54570_CR46","doi-asserted-by":"publisher","unstructured":"Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J. Clin. Investig. 126 4119\u20134124. https:\/\/doi.org\/10.1172\/JCI89067","DOI":"10.1172\/JCI89067"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54570-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54570-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54570-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:44:54Z","timestamp":1786664694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-54570-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["54570"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-54570-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8501287\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25410"}}